Details for Patent: 10,828,297
✉ Email this page to a colleague
Which drugs does patent 10,828,297 protect, and when does it expire?
Patent 10,828,297 protects AKYNZEO and is included in two NDAs.
This patent has sixty-eight patent family members in forty-one countries.
Summary for Patent: 10,828,297
| Title: | Compositions and methods for treating centrally mediated nausea and vomiting |
| Abstract: | Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery. |
| Inventor(s): | Trento; Fabio (Pare, IT), Cantoreggi; Sergio (Cagiallo, CH), Rossi; Giorgia (Cernobbio, IT), Cannella; Roberta (Varese, IT), Bonadeo; Daniele (Casalzuigno, IT) |
| Assignee: | Helsinn Healthcare SA (Lugano/Pazzallo, CH) |
| Application Number: | 15/923,050 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; |
Drugs Protected by US Patent 10,828,297
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Helsinn Hlthcare | AKYNZEO | netupitant; palonosetron hydrochloride | CAPSULE;ORAL | 205718-001 | Oct 10, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY | ⤷ Sign Up | ||||
| Helsinn Hlthcare | AKYNZEO | fosnetupitant chloride hydrochloride; palonosetron hydrochloride | POWDER;INTRAVENOUS | 210493-001 | Apr 19, 2018 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY | ⤷ Sign Up | ||||
| Helsinn Hlthcare | AKYNZEO | fosnetupitant chloride hydrochloride; palonosetron hydrochloride | SOLUTION;INTRAVENOUS | 210493-002 | May 27, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,828,297
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 3083 | ⤷ Sign Up | |||
| Australia | 2010320598 | ⤷ Sign Up | |||
| Brazil | 112012011485 | ⤷ Sign Up | |||
| Canada | 2778301 | ⤷ Sign Up | |||
| Chile | 2012001276 | ⤷ Sign Up | |||
| China | 102655864 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
